Pirralkonium is the antiseptic agent.

Auriclosene (previously known as NVC-422) is a broad-spectrum, fast-acting topical anti-infective agent against microbial pathogens, including antibiotic-resistant microbes. It has been investigated in phase II clinical trials for the treatment of bacterial conjunctivitis and as a topical gel in children with impetigo. In addition, using a guinea pig model was shown, that auriclosene was effective in the treatment of dermatophytosis, including onychomycosis.

Disiquonium is a quaternary ammonium derivative. It was developed as antiseptic agent.

Aditoprim is a long-acting, selective, reversible inhibitor of dihydrofolate reductase with application as a broad-spectrum antibacterial agent in animals. Aditoprim is low toxic and not mutagenic.Many gram-positive and gram-negative bacteria are highly susceptible or susceptible to Aditoprim, especially Salmonella and Streptococcus, while H. parasuis and Klebsiella were moderately susceptible to Aditoprim. Phase II clinical study of Aditoprim on therapeutic effect on swine streptococcosis has demonstrated that Aditoprim is as active as compound sulfadiazine, which provides reasonable theoretical foundation for the clinical application of Aditoprim.

Nifuroquine is an antibacterial agent, used in the treatment of bovine mastitis.

Albaconazole is a triazole antifungal. Azoles are important antifungal compounds, and all drugs in this class inhibit ergosterol synthesis by blocking the 14-α-demethylase enzyme, resulting in the accumulation of toxic methylsterols that may culminate in fungal death. Albaconazole, an oral agent that has demonstrated high levels of bioavailability and potent antifungal activity. It was under development for the treatment of onychomycosis, vulvovaginal candidiasis. Also, albaconazole was evaluated in phase I, a randomized, placebo-controlled clinical trial in patients with tinea pedis. No serious adverse effects occurred in the studies involving albaconazole. However, this researches on this drug were discontinued.

Dofamium is the antiseptic agent. It was used for the water sterilization.

Drazidox is the antiseptic agent.

Aliconazole is an antifungal imidazole derivative, developed by Knoll Pharmaceuticals. Aliconazole was previously in phase III clinical trials for the determination of efficacy in the topical treatment of cutaneous fungal infections. The proposed use includes superficial fungal infections, including dermatomycoses, tinea versicolor, and cutaneous and vaginal candidiasis

Pirbenicillin is a broad-spectrum semisynthetic penicillin with activity against both gram-positive cocci and gram-negative bacilli. Pirbenicillin is less active than either carbenicillin or ticarcillin against Proteus spp. It is as active as carbenicillin against Serratia spp. and Enterobacter spp. Pirbenicillin demonstrated eight- and fourfold better minimal bactericidal concentration values towards Pseudomonas isolates than those of carbenicillin and ticarcillin, respectively. Pirbenicillin binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. The drug is somewhat more stable in serum than carbenicillin. Pirbenicillin does not appear to inactivate gentamicin as rapidly as carbenicillin.